VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Rhea-AI Summary

VYNE Therapeutics Inc. (Nasdaq: VYNE), a clinical-stage biopharmaceutical company, announced that CEO David Domzalski will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference on March 7, 2023. The event will take place at 2:10 PM ET at the Boston Marriott Copley Place, where management will also hold 1-on-1 meetings with investors. A webcast link is provided for attendees to view the session online. The webcast replay will be accessible for 90 days post-conference. VYNE is focused on developing therapies for immuno-inflammatory conditions through its proprietary bromodomain & extra-terminal (BET) domain platform.

BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the 43^rd Annual Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts, on March 7, 2023. Management will also be available for 1-on-1 meetings with investors.

43^rd Annual Cowen Health Care Conference Presentation Details

Fireside Chat:	Tuesday, March 7th, 2023, at 2:10 PM ET
Speaker:	David Domzalski, President and Chief Executive Officer
Registration:	Webcast Link
1-on-1: Meetings:	March 7, 2023

The replay of the webcast will be available on the VYNE website for 90 days following the conference.

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com 

FAQ

What is the date and time of VYNE's presentation at the Cowen Health Care Conference?

VYNE's presentation will take place on March 7, 2023, at 2:10 PM ET.

Who is the CEO of VYNE Therapeutics participating in the fireside chat?

David Domzalski, President and Chief Executive Officer, will participate in the fireside chat.

Where is the 43rd Annual Cowen Health Care Conference being held?

The conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts.

How can I access the webcast for VYNE's presentation at the conference?

You can access the webcast through a link provided in VYNE's press release.

Will there be a replay of VYNE's conference presentation?

Yes, the replay of the webcast will be available on VYNE's website for 90 days after the conference.